Ischemic Injury
Interventional stroke program not superior to standard care at 1 year
No differences in incidence of vascular events were observed in adults with ischemic stroke who received interventional care compared with standard care 1 year after baseline assessment, data show.
Cerebral embolic protection device for TAVR safe, but not superior vs. standard care
In the REFLECT II study, a cerebral embolic protection device for patients undergoing transcatheter aortic valve replacement beat safety performance goals, but it was not more effective than standard care.
ISAR-REACT 5
Ticagrelor (Brilinta, AstraZeneca) vs. prasugrel (Effient, Daiichi Sankyo/Eli Lilly) on clinical outcomes in patients with ACS undergoing a planned invasive strategy.
Smaller prasugrel dose maintains protective benefits vs. standard ticagrelor dose in ACS
A reduced dose of prasugrel in patients with ACS maintained its anti-ischemic effect without elevated bleeding risk compared with patients treated with a standard dose of ticagrelor, regardless of age or weight, researchers found.
Early intervention in NSTEACS reduces ischemic events but not CV mortality
Confirming previously presented findings, early intervention for patients who presented with non-ST-segment elevation ACS without pretreatment with P2Y12 inhibitors reduced recurrent ischemic events compared with delayed coronary angiography, but there were no differences in CV mortality.